Background: : The treatment of pregnant women with opioid use disorder is challenging due to the myriad of physical, mental, and social complications. Factors influencing adherence to buprenorphine during pregnancy have not been identified. Materials and methods: : Pregnant women with opioid use disorder followed in a tertiary clinic were included in a retrospective chart review from buprenorphine induction through delivery. All women who had been evaluated and treated with buprenorphine from January 1, 2014, to September 31, 2016, were included. Adherence was defined as follows: 1) adherent: attended follow up visits, negative urine toxicology screens, and phase advancement; 2) moderately adherent: attended follow up visits until delivery, had not completed six negative urine toxicology screens, or had positive urine toxicology screens (i.e., no phase advancement); 3) non-adherent: missed follow up visits and did not stay in treatment until delivery. Sociodemographic characteristics, family psychiatric history, current and lifetime psychiatric and childhood trauma along with treatment factors were compared by category of adherence. Results: : 64 women met criteria for inclusion in this study with 41 (64%) adherent; eight (13%) moderately adherent; and 15 (23%) non-adherent. In the non-adherent group compared to the adherent group, the clinicianrated opioid withdrawal scale score was significantly higher, and the daily buprenorphine dose at last visit was significantly lower. Conclusions: : Women who were non-adherent to buprenorphine during pregnancy had higher severity of opioid withdrawal symptoms and lower doses of buprenorphine. These findings should be further explored with the goal of optimizing care without increasing risk for neonates.
Introduction
The national opioid crisis has increased attention on the treatment of pregnant women with opioid use disorder (OUD). Recent literature reports an increase in opioid prescriptions during pregnancy and parallels between an increase in the prevalence of OUD during pregnancy and the number of women seeking OUD treatment Desai et al., 2014; Martin et al., 2015) . American College of Obstetrics and Gynecologists (ACOG), 2012 and World Health Organization (WHO), 2014 Treatment Guidelines recommend medication-assisted treatment (MAT) with methadone or buprenorphine (BUP) during pregnancy in women with identified OUD.
Treatment of OUD during pregnancy is largely based on the goals of increasing prenatal care, decreasing illicit substance use, and improving outcomes for infants compared to non-treated OUD. The landmark MOTHER study comparing maintenance medications for OUD in pregnancy demonstrated a significant difference in attrition between pregnant women randomized to methadone (n = 73 completers) versus buprenorphine (n = 58 completers) (Jones et al., 2010) . Notably, 71% of the women in the buprenorphine group who dropped out reported being "dissatisfied" with buprenorphine. In order for treatment to be effective and attain the goals noted above, treatment adherence is essential. To our knowledge, factors influencing adherence to buprenorphine treatment during pregnancy have not been identified. The current study was a retrospective exploratory analysis of factors that may influence adherence to buprenorphine treatment during pregnancy.
Material and methods
The Women's Mental Health Program (WMHP) at the University of Arkansas for Medical Sciences (UAMS) is located in a tertiary academic setting and receives referrals across the state for treatment of mental illness, including substance use disorders, during pregnancy and up to one year postpartum. A retrospective chart review of pregnant women with OUD treated with buprenorphine was performed including women who were treated as an outpatient from January 1, 2014, to September 31, 2016. Women were included if they had at least one outpatient appointment and were prescribed buprenorphine, but there were no other exclusion criteria. After referral to the WMHP, pregnant women with opioid use disorder on buprenorphine were clinically enrolled in a phase-advancement clinic that started as weekly visits during Phase 1, with advancement to subsequent phases (Phase 2 -bimonthly visits, Phase 3 -monthly visits) based on negative, observed urine toxicology for illicit substances as well as compliance with group therapy and follow-up visits for medication management. Every clinic visit included an observed urine drug screen, medication management with a psychiatrist, one-hour group therapy, and both patient (i.e., Subjective Opiate Withdrawal Scale) and clinician (i.e., Clinical Opiate Withdrawal Scale) rated scales of opioid withdrawal symptoms. This study was approved by the University of Arkansas for Medical Sciences Institutional Review Board.
Subjects were categorized into three groups: 1) adherent: attended follow up visits, negative urine toxicology screens, and phase advancement; 2) moderately adherent: attended follow up visits until delivery, had not completed six negative urine toxicology screens, or had positive urine toxicology screens (i.e., no phase advancement); 3) non-adherent: missed follow up visits and did not stay in treatment until delivery. This was an exploratory analysis of factors associated with buprenorphine success including lifetime psychiatric diagnoses [i.e., structured clinical interview (SCID-IV)], childhood trauma (i.e., Childhood Trauma Questionnaire), and sociodemographic characteristics. Continuous variables were compared using one-way ANOVA, and all other variables were compared separately by 1) adherent vs. moderately adherent and 2) adherent vs. non-adherent using the z-test to compare proportions (SigmaPlot).
Results
A total of 64 pregnant women with OUD and prescribed buprenorphine were included and were categorized as follows: 1) 41 (64%) adherent; 2) Eight (13%) moderately adherent, and 3) 15 (23%) nonadherent. There were no sociodemographic differences between the three groups. The findings were inconclusive as to whether or not an association was present for both comorbid psychiatric illness or childhood trauma (Table 1) .
In the non-adherent group, examination of treatment-related variables demonstrated a significantly higher clinician-rated opioid withdrawal scale score at last visit (p = 0.035) and a lower daily dose of buprenorphine (mg/day) at last visit (p = 0.006) compared to the two adherent groups ( Table 2) . As expected, the non-adherent group also had a less total number of days in treatment and scheduled visits than the adherent groups.
Discussion
This study provided novel data on factors associated with adherence to buprenorphine treatment during pregnancy with a retention rate similar to those previously published in non-pregnant women (Kakko et al., 2003) . We found significantly higher clinician-rated withdrawal scores and lower buprenorphine daily dose at the last visit suggesting that adherence during pregnancy in the current sample was influenced by the severity of withdrawal symptoms and clinical response (i.e., dosing strategy). It is feasible that non-adherent pregnant women may have left treatment prior to dose optimization. Adherent women had more days in treatment and more scheduled appointments compared to the other two groups that did not seem to be impacted by gestational time of enrollment. Our previous study in a non-pregnant population suggested that early childhood trauma was associated with adherence (Kumar et al., 2016) ; however, it was inconclusive that a history of childhood trauma or co-morbid psychiatric illnesses impacted adherence to treatment during pregnancy. Of importance, the majority of the women in this study did have a co-morbid psychiatric illness (range 71-100%) and childhood trauma (averaging low to moderate levels across all trauma types) that is congruent with biopsychosocial development models of substance use disorders.
Limitations include a small sample size that may not have allowed the detection of significant differences, specifically for co-morbid psychiatric illness and impact of childhood trauma. We were also limited by the inability to re-contact women to determine reasons for discontinuation in the treatment. There is no indication that participants informed clinicians they were dissatisfied with treatment prior to nonadherence.
In order to optimize adherence to treatment during pregnancy, these data suggested that more aggressive buprenorphine dosing strategies early in treatment targeting rapid control of withdrawal symptoms may enhance adherence through delivery. In this current study, dosing was not based on a standard protocol, and medication was increased based on clinical assessment and patient reports. Notably, Jones et al. (2010) utilized a less aggressive buprenorphine dosing strategy of 2 mg increments. The optimal dosing strategy must be weighed against potential risks to neonates during the postpartum period warranting further exploration regarding the impact of dosing on outcomes as current evidence is inconclusive. Induction of MAT in an inpatient setting may provide prompt symptom control; however, adherence did not seem impacted based on inpatient versus outpatient induction of BUP.
To our knowledge, this is the first study that examined factors associated with buprenorphine adherence during pregnancy. In a comparable study completed at 12 months postpartum (O'Connor et al., 2018) , women who entered treatment prior to 13 weeks' gestation were more likely to remain in treatment. Our current study did not find that gestational timing of enrollment significantly differed between adherence groups.
Conclusions
Severity of withdrawal symptoms and lower doses of buprenorphine were associated with non-adherence to buprenorphine treatment during pregnancy until delivery. Further studies on optimizing buprenorphine management (i.e., dosing protocols) during pregnancy are warranted to improve adherence.
Contributors
Dr. Coker contributed to the overall project aims, gathering and collection of data, obtaining IRB approval, drafting and editing of manuscript and submission process. Mr. Catlin contributed to the overall project aims, collection and organization of data, and editing of manuscript. Dr. Ray-Griffith contributed to the overall project aims, gathering and collection of data, and editing of manuscript. Ms. Knight contributed to the collection of data and editing of manuscript. Dr. Stowe contributed to the overall project aims, collection of data, and editing of manuscript. All authors read and approved final manuscript. Coker et al. Drug and Alcohol Dependence 192 (2018) 146-149 Advancing Translational Sciences; and the National Institute on Drug Abuse [grant number 2T32DA022981-06].
Role of funding source
The support had no role in the design, analysis, interpretation, or publication of this study. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIDA or NIH.
Conflict of interest
Dr. Coker has received research support from Arkansas Children's Research Institute and National Institute on Drug Abuse. She has served as a physician (non-compensated) on clinical trials sponsored by SAGE, Janssen, and Boerhringer Ingelheim Pharmaceuticals. She has never served as a consultant to any biomedical or pharmaceutical corporation. Neither she nor family members have ever held equity positions in biomedical or pharmaceutical corporations.
Mr. Catlin has no potential conflicts of interest. Dr. Ray-Griffith currently receives clinical trial support from Neuronetics and has received clinical trial support from Sage Therapeutics. She has never served as a consultant to any biomedical or pharmaceutical corporation. Neither her nor family members have ever held equity positions in biomedical or pharmaceutical corporations.
Ms. Knight currently receives research support from the National J.L. Coker et al. Drug and Alcohol Dependence 192 (2018) 146-149 Institutes of Health (NIH). Her adult son is employed by GlaxoSmithKline and has stock options as part of his employment. Dr. Stowe has received research support from Eli Lilly, Glaxo SmithKline (GSK), Janssen, Sage Therapeutics, the National Institutes of Health (NIH), and Wyeth. He has served on speakers' bureaus and/or received honoraria from Eli Lilly, GSK, Pfizer and Wyeth. He has served on advisory boards for GSK, and BSM. Neither he nor family members have ever held equity positions in biomedical or pharmaceutical corporations.
